AAPL342.46-1.01 (-0.29%) ▼|ABBV283.23-2.19 (-0.77%) ▼|ABT103.77-1.12 (-1.07%) ▼|ACN231.93+2.25 (+0.98%) ▲|ADBE244.88-0.33 (-0.13%) ▼|AMAT423.98+14.69 (+3.59%) ▲|AMD548.48+19.73 (+3.73%) ▲|AMGN427.01-5.49 (-1.27%) ▼|AMT182.77-2.50 (-1.35%) ▼|AMZN262.97+12.97 (+5.19%) ▲|AVGO339.14+10.39 (+3.16%) ▲|AXP313.39-0.21 (-0.07%) ▼|BA191.44+1.23 (+0.64%) ▲|BAC50.53-0.71 (-1.38%) ▼|BKNG161.04-2.41 (-1.47%) ▼|BLK1,128.55-5.83 (-0.51%) ▼|BMY58.66-1.10 (-1.83%) ▼|BNY143.11-0.20 (-0.14%) ▼|BRK-B530.62-1.41 (-0.26%) ▼|C122.91-1.35 (-1.09%) ▼|CAT730.66-0.10 (-0.01%) ▼|CL93.04-1.07 (-1.14%) ▼|CMCSA21.72-0.19 (-0.84%) ▼|COF199.66-2.08 (-1.03%) ▼|COP144.69-1.82 (-1.24%) ▼|COST990.00+0.89 (+0.09%) ▲|CRM239.54-1.16 (-0.48%) ▼|CSCO107.35-0.04 (-0.04%) ▼|CVS91.22-1.14 (-1.23%) ▼|CVX223.64-1.35 (-0.60%) ▼|DE629.94-11.92 (-1.86%) ▼|DHR225.22-3.82 (-1.67%) ▼|DIS109.71-0.89 (-0.80%) ▼|DUK119.56-1.92 (-1.58%) ▼|EMR161.73+0.26 (+0.16%) ▲|FDX292.88-0.67 (-0.23%) ▼|GD341.62-2.61 (-0.76%) ▼|GE312.35-1.48 (-0.47%) ▼|GEV921.84+0.64 (+0.07%) ▲|GILD154.68-1.51 (-0.97%) ▼|GM82.42-1.54 (-1.83%) ▼|GOOG341.25+4.34 (+1.29%) ▲|GOOGL345.42+4.83 (+1.42%) ▲|GS881.36+0.10 (+0.01%) ▲|HD309.40-0.23 (-0.07%) ▼|HON211.09-0.33 (-0.15%) ▼|IBM236.12+3.98 (+1.71%) ▲|INTC94.58+4.73 (+5.26%) ▲|INTU321.82-3.33 (-1.02%) ▼|ISRG432.22+5.52 (+1.29%) ▲|JNJ252.70-2.86 (-1.12%) ▼|JPM335.60-4.12 (-1.21%) ▼|KO93.60-0.30 (-0.32%) ▼|LIN501.56+3.13 (+0.63%) ▲|LLY1,248.36-8.67 (-0.69%) ▼|LMT549.50-2.59 (-0.47%) ▼|LOW195.48-1.91 (-0.97%) ▼|LRCX278.52+14.58 (+5.52%) ▲|MA613.06-4.36 (-0.71%) ▼|MCD242.34-0.64 (-0.26%) ▼|MDLZ63.57-0.34 (-0.53%) ▼|MDT92.88-1.88 (-1.98%) ▼|META703.34-5.99 (-0.84%) ▼|MMM163.79-0.96 (-0.58%) ▼|MO74.23-0.88 (-1.17%) ▼|MRK144.60-1.35 (-0.93%) ▼|MS179.96-0.61 (-0.34%) ▼|MSFT534.15+5.10 (+0.96%) ▲|MU919.77+40.93 (+4.66%) ▲|NEE78.56-1.24 (-1.55%) ▼|NFLX69.68-0.86 (-1.21%) ▼|NKE36.84-0.30 (-0.79%) ▼|NOW143.89+1.92 (+1.35%) ▲|NVDA219.54+5.41 (+2.53%) ▲|ORCL130.69+2.46 (+1.91%) ▲|PEP132.38+0.89 (+0.68%) ▲|PFE29.30-0.29 (-0.96%) ▼|PG157.22-2.13 (-1.34%) ▼|PLTR196.03+10.00 (+5.38%) ▲|PM201.78-3.42 (-1.67%) ▼|QCOM173.83+1.72 (+1.00%) ▲|RTX191.84-2.09 (-1.08%) ▼|SBUX97.95+0.43 (+0.44%) ▲|SCHW90.19-1.77 (-1.92%) ▼|SO89.67-1.52 (-1.66%) ▼|SPG203.50-1.94 (-0.94%) ▼|T23.11-0.34 (-1.43%) ▼|TMO677.03-12.97 (-1.88%) ▼|TMUS157.62-1.48 (-0.93%) ▼|TSLA367.63+12.91 (+3.64%) ▲|TXN274.55-1.93 (-0.70%) ▼|UBER70.39+0.04 (+0.05%) ▲|UNH401.77+0.34 (+0.08%) ▲|UNP286.76-2.28 (-0.79%) ▼|UPS97.32-0.17 (-0.17%) ▼|USB58.21-0.53 (-0.89%) ▼|V401.95-0.67 (-0.17%) ▼|VZ44.11-0.68 (-1.52%) ▼|WFC82.17-1.71 (-2.03%) ▼|WMT118.35-0.47 (-0.39%) ▼|XOM177.58-1.40 (-0.78%) ▼|AAPL342.46-1.01 (-0.29%) ▼|ABBV283.23-2.19 (-0.77%) ▼|ABT103.77-1.12 (-1.07%) ▼|ACN231.93+2.25 (+0.98%) ▲|ADBE244.88-0.33 (-0.13%) ▼|AMAT423.98+14.69 (+3.59%) ▲|AMD548.48+19.73 (+3.73%) ▲|AMGN427.01-5.49 (-1.27%) ▼|AMT182.77-2.50 (-1.35%) ▼|AMZN262.97+12.97 (+5.19%) ▲|AVGO339.14+10.39 (+3.16%) ▲|AXP313.39-0.21 (-0.07%) ▼|BA191.44+1.23 (+0.64%) ▲|BAC50.53-0.71 (-1.38%) ▼|BKNG161.04-2.41 (-1.47%) ▼|BLK1,128.55-5.83 (-0.51%) ▼|BMY58.66-1.10 (-1.83%) ▼|BNY143.11-0.20 (-0.14%) ▼|BRK-B530.62-1.41 (-0.26%) ▼|C122.91-1.35 (-1.09%) ▼|CAT730.66-0.10 (-0.01%) ▼|CL93.04-1.07 (-1.14%) ▼|CMCSA21.72-0.19 (-0.84%) ▼|COF199.66-2.08 (-1.03%) ▼|COP144.69-1.82 (-1.24%) ▼|COST990.00+0.89 (+0.09%) ▲|CRM239.54-1.16 (-0.48%) ▼|CSCO107.35-0.04 (-0.04%) ▼|CVS91.22-1.14 (-1.23%) ▼|CVX223.64-1.35 (-0.60%) ▼|DE629.94-11.92 (-1.86%) ▼|DHR225.22-3.82 (-1.67%) ▼|DIS109.71-0.89 (-0.80%) ▼|DUK119.56-1.92 (-1.58%) ▼|EMR161.73+0.26 (+0.16%) ▲|FDX292.88-0.67 (-0.23%) ▼|GD341.62-2.61 (-0.76%) ▼|GE312.35-1.48 (-0.47%) ▼|GEV921.84+0.64 (+0.07%) ▲|GILD154.68-1.51 (-0.97%) ▼|GM82.42-1.54 (-1.83%) ▼|GOOG341.25+4.34 (+1.29%) ▲|GOOGL345.42+4.83 (+1.42%) ▲|GS881.36+0.10 (+0.01%) ▲|HD309.40-0.23 (-0.07%) ▼|HON211.09-0.33 (-0.15%) ▼|IBM236.12+3.98 (+1.71%) ▲|INTC94.58+4.73 (+5.26%) ▲|INTU321.82-3.33 (-1.02%) ▼|ISRG432.22+5.52 (+1.29%) ▲|JNJ252.70-2.86 (-1.12%) ▼|JPM335.60-4.12 (-1.21%) ▼|KO93.60-0.30 (-0.32%) ▼|LIN501.56+3.13 (+0.63%) ▲|LLY1,248.36-8.67 (-0.69%) ▼|LMT549.50-2.59 (-0.47%) ▼|LOW195.48-1.91 (-0.97%) ▼|LRCX278.52+14.58 (+5.52%) ▲|MA613.06-4.36 (-0.71%) ▼|MCD242.34-0.64 (-0.26%) ▼|MDLZ63.57-0.34 (-0.53%) ▼|MDT92.88-1.88 (-1.98%) ▼|META703.34-5.99 (-0.84%) ▼|MMM163.79-0.96 (-0.58%) ▼|MO74.23-0.88 (-1.17%) ▼|MRK144.60-1.35 (-0.93%) ▼|MS179.96-0.61 (-0.34%) ▼|MSFT534.15+5.10 (+0.96%) ▲|MU919.77+40.93 (+4.66%) ▲|NEE78.56-1.24 (-1.55%) ▼|NFLX69.68-0.86 (-1.21%) ▼|NKE36.84-0.30 (-0.79%) ▼|NOW143.89+1.92 (+1.35%) ▲|NVDA219.54+5.41 (+2.53%) ▲|ORCL130.69+2.46 (+1.91%) ▲|PEP132.38+0.89 (+0.68%) ▲|PFE29.30-0.29 (-0.96%) ▼|PG157.22-2.13 (-1.34%) ▼|PLTR196.03+10.00 (+5.38%) ▲|PM201.78-3.42 (-1.67%) ▼|QCOM173.83+1.72 (+1.00%) ▲|RTX191.84-2.09 (-1.08%) ▼|SBUX97.95+0.43 (+0.44%) ▲|SCHW90.19-1.77 (-1.92%) ▼|SO89.67-1.52 (-1.66%) ▼|SPG203.50-1.94 (-0.94%) ▼|T23.11-0.34 (-1.43%) ▼|TMO677.03-12.97 (-1.88%) ▼|TMUS157.62-1.48 (-0.93%) ▼|TSLA367.63+12.91 (+3.64%) ▲|TXN274.55-1.93 (-0.70%) ▼|UBER70.39+0.04 (+0.05%) ▲|UNH401.77+0.34 (+0.08%) ▲|UNP286.76-2.28 (-0.79%) ▼|UPS97.32-0.17 (-0.17%) ▼|USB58.21-0.53 (-0.89%) ▼|V401.95-0.67 (-0.17%) ▼|VZ44.11-0.68 (-1.52%) ▼|WFC82.17-1.71 (-2.03%) ▼|WMT118.35-0.47 (-0.39%) ▼|XOM177.58-1.40 (-0.78%) ▼|
15.1 C
New York
Monday, October 19, 2026

Tag: tumor cells

newssourceFORcompanycontentinformation1releasesmarket

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentationUpdated first-line...

Myosin Therapeutics Invited to Present at BioFuture 2026 in New York City

JUPITER, Fla., Oct. 16, 2026 /PRNewswire/ -- Myosin Therapeutics today announced that, following its selection as a 2026–2027 National Cancer Institute (NCI) SBIR Investor Initiatives...

Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs,...

The neuroendocrine prostate cancer market is expected to grow steadily, driven by the rising recognition of NEPC as an aggressive and treatment-resistant form of...

Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs,...

The neuroendocrine prostate cancer market is expected to grow steadily, driven by the rising recognition of NEPC as an aggressive and treatment-resistant form of...

Tethis, MACS and Everex announce transfer of See.d® business unit and long-term manufacturing partnership

MILAN, Sept. 21, 2026 /PRNewswire/ -- Standardized preparation of blood-derived cellular samples is the foundation for reproducible liquid biopsy, digital cytology, and AI-assisted cell...

Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell

— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI.— The Company is...

Tethis announces application note of SmartBioSurface® slides for cell suspension workflows on leading spatial biology platform

MILAN, June 15, 2026 /PRNewswire/ -- Addressing a critical technical limitation in multi-cycle imaging - the reliable adhesion and retention of suspension-derived, non-adherent cells...

Tethis announces application note of SmartBioSurface® slides for cell suspension workflows on leading spatial biology platform

MILAN, June 15, 2026 /PRNewswire/ -- Addressing a critical technical limitation in multi-cycle imaging - the reliable adhesion and retention of suspension-derived, non-adherent cells...

Enterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics™-induced CD8 T cell responses and clinical activity

Enterome presented new interim data from the ongoing Phase 1/2 SIDNEY study of OncoMimics™ EO2463 in patients with indolent non-Hodgkin lymphoma.

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026.

Rakuten Medical Announces Executive Leadership Transition to Enhance Operational Execution and Organizational Discipline as a Global, Scalable Biotech Company

Minami Maeda appointed as CEO to drive faster, more focused execution toward U.S. commercial launchMickey Mikitani will continue to provide strategic direction and remains...

Tethis to launch SmartBioSurface® slides at EACR Conference

MILAN, June 8, 2026 /PRNewswire/ -- Tethis S.p.A., a pioneering life sciences and diagnostics company, today announces the commercial launch of SmartBioSurface slides, an...

World’s First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory...

SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and...

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTumor cells

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers